Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial
Primary result · New-onset diabetesResult — go to the resultHazard ratio 0.76 95% CI 0.59–0.97Authors' conclusion
In participants with heart failure with mildly reduced or preserved ejection fraction without diabetes, oral finerenone reduced the hazard of new-onset diabetes, representing a meaningful additional clinical benefit of this treatment in these individuals.
Study context
- Population
- Participants with HF, NYHA class II–IV, LVEF 40% or higher, structural heart disease and elevated NT-proBNP, without diabetes at baseline (history of diabetes or baseline HbA1c ≥6.5% excluded)without diabetes at baseline
- Participants
- 3,222 participants
- Comparison
- Oral finerenone vs placebo
Methodological detailsdouble-blind, placebo-controlled, Recruited Sept 14, 2020 to Jan 10, 2023; 6001 randomised in parent trial
- Double-blind
- Placebo-controlled
- Recruited Sept 14, 2020 to Jan 10, 2023; 6001 randomised in parent trial
Primary result
New-onset diabetes · median follow-up 31.3 months
Hazard ratio
0.76
95% CI 0.59–0.97
P = 0.026
Events by treatment group
Finerenonevs Placebo
HR 0.76 (95% CI 0.59–0.97); P = 0.026
As reported in the abstract
Further findings
| Outcome | Subdistribution HR (CI) | P value | |
|---|---|---|---|
| New-onset diabetes, Fine-Gray competing risk analysis (competing risk of death) | 0.75 (0.59–0.96) | P = 0.024 | |
| 0.512Subdistribution hazard ratio (log scale) |
Sensitivity analyses (expanded or restricted definitions; excluding baseline glucose-lowering drug users, n=15)
- Results were similar
Subgroups
- Effect consistent across key participant subgroups
Safety
- Participants with adverse event of new diabetes not captured by any definition
- 7
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial. Lancet Diabetes Endocrinol. Published 13 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →